major
theme
nacfc
develop
therapeut
strategi
normal
cystic
fibrosi
transmembran
conduct
regul
cftr
protein
function
patient
note
plenari
session
workshop
symposia
achiev
goal
requir
varieti
approach
address
numer
diseas
caus
cftr
mutat
includ
develop
potent
correctorspotenti
improv
drug
prematur
truncat
mutat
gene
therapi
stem
cell
base
approach
cftr
mutat
amen
pharmacolog
treatment
nearli
cf
patient
north
america
harbor
least
one
copi
data
present
two
corrector
significantli
enhanc
process
traffick
combin
first
gener
corrector
potenti
assay
grootenhui
et
al
similarli
novel
corrector
exhibit
increas
potenc
correct
rel
exist
cftr
corrector
singh
et
al
novel
approach
improv
transport
also
show
promis
screen
strategi
use
identifi
small
molecul
inhibitor
endocyt
adapt
modul
intern
cftr
madden
et
al
inhibitor
enhanc
activ
mutant
conjunct
corrector
potenti
promis
mani
new
drug
enter
human
trial
abil
provid
safe
effect
improv
cftr
activ
remain
unproven
drug
design
rescu
help
patient
carri
least
one
copi
mutat
like
benefit
mutat
prematur
termin
codon
ptc
mutat
cftr
treat
use
readthrough
agent
bypass
stop
codon
permit
express
full
length
cftr
initi
clinic
studi
readthrough
agent
base
aminoglycosid
disappoint
possibl
due
interact
inhal
screen
strategi
recent
identifi
herbal
extract
escin
substanti
readthrough
activ
sharma
et
al
howev
previou
studi
suggest
escin
readthrough
agent
may
requir
combin
therapi
cftr
modul
achiev
clinic
relev
inde
sever
investig
demonstr
combin
readthrough
agent
cftr
modul
includ
corrector
potenti
nonsens
mediat
decay
inhibitor
improv
cftr
activ
ptc
mutant
mutyam
et
al
bihler
et
al
although
strategi
outlin
benefit
major
cf
patient
remain
whose
mutat
address
via
genet
approach
common
method
gene
therapi
use
viral
vector
studi
cf
pig
demonstr
feasibl
use
lentiviru
hybrid
piggybackaav
vector
restor
cftr
activ
et
al
recent
technolog
emerg
excit
new
approach
toward
target
gene
repair
methodolog
shown
correct
deep
intron
splice
mutant
human
tracheal
epitheli
cell
sanz
et
al
promis
approach
like
need
pair
stem
cell
technolog
deliv
cell
repair
cftr
lung
ghaedi
remain
emerg
altern
approach
util
target
rna
edit
correct
mutat
translat
shown
restor
function
cftr
activ
ptc
mutat
et
al
though
util
somewhat
limit
potenti
target
effect
strategi
improv
cftr
function
offer
best
hope
eventu
cure
cf
even
best
drug
date
complet
elimin
diseas
remain
urgent
need
improv
therapi
address
airway
mucu
abnorm
infect
inflamm
character
cf
one
promis
novel
approach
lie
use
lyas
inhibitor
shown
reduc
airway
inflamm
mutant
mous
model
veltman
et
al
similarli
hypothiocyanit
shown
inactiv
bacteri
thioredoxin
reductas
enhanc
bacteri
kill
day
et
al
mucu
also
shown
import
therapeut
target
mani
anim
model
demonstr
presenc
dehydr
mucu
abnorm
viscoelast
properti
row
birket
even
young
children
cf
elev
concentr
rheolog
abnorm
mucu
esther
et
al
develop
new
therapi
requir
appropri
model
biomark
assess
therapeut
effect
sever
investig
present
recent
advanc
tool
one
emerg
model
use
special
cultur
techniqu
grow
epitheli
cell
obtain
patient
biopsi
spheroid
organoid
swell
shrink
respons
cftr
modul
berker
et
al
assay
base
organoid
obtain
airway
cell
shown
predict
respons
rare
cftr
mutat
modul
better
total
protein
chlorid
current
measur
cholon
et
al
viscoelast
properti
mucu
organoid
correl
efficaci
cftr
modul
mellnick
et
al
addit
intestin
organoid
shown
use
develop
patient
specif
screen
platform
novel
therapi
vonk
et
al
ideal
new
therapeut
strategi
would
test
anim
model
gener
anim
model
faith
recapitul
human
diseas
remain
elus
one
potenti
excit
new
approach
use
technolog
gener
cftr
defici
rabbit
appear
exhibit
mani
airway
liver
phenotyp
clinic
diseas
less
expens
maintain
cf
pig
larger
anim
model
xu
et
al
also
shown
use
quickli
creat
mous
model
specif
cftr
mutat
valerio
et
al
hodg
et
al
may
find
valu
test
efficaci
novel
cftr
modul
even
though
cf
mice
develop
signific
airway
diseas
exist
model
includ
cf
ferret
pig
continu
provid
import
insight
cf
ferret
shown
develop
bronchiectasi
even
absenc
bacteri
infect
rosen
et
al
studi
cf
pig
suggest
airway
acidif
via
may
novel
therapeut
target
shah
et
al
data
open
label
extens
studi
lumacaftorivacaftor
along
experi
present
sever
investig
progress
studi
parallel
group
extens
studi
lumacaftorivacaftor
follow
traffic
transport
clinic
trial
present
subsequ
publish
konstan
et
al
particip
age
year
age
older
homozyg
mutat
n
complet
week
treatment
traffic
transport
elig
enrol
progress
particip
receiv
lumacaftorivacaftor
one
two
dose
level
week
efficaci
result
particip
fda
approv
dose
lumacaftorivacaftor
n
present
studi
struggl
high
number
withdraw
particularli
follow
commerci
avail
particip
complet
week
complet
week
safeti
find
similar
seen
traffic
transport
respiratori
symptom
common
elev
liver
transaminas
upper
limit
normal
uln
approxim
patient
emerg
new
advers
event
week
includ
initi
studi
period
treatment
reduct
pulmonari
exacerb
pex
document
initi
clinic
trial
persist
improv
baselin
bodi
mass
index
bmi
continu
increas
progress
although
declin
time
occur
annual
rate
ci
less
treat
group
compar
match
control
group
cf
foundat
patient
registri
cffpr
impact
ivacaftor
clinic
outcom
examin
use
data
cffpr
uk
cf
patient
registri
bessonova
et
al
data
use
compar
patient
ivacaftor
n
us
uk
match
untreat
patient
n
us
uk
rel
risk
death
organ
transplant
hospit
pex
significantli
lower
us
popul
ivacaftor
compar
untreat
group
similar
trend
seen
uk
rate
pseudomona
aeruginosa
pa
infect
also
trend
lower
ivacaftor
group
separ
uk
patient
registri
data
use
examin
clinic
outcom
patient
ivacaftor
first
two
year
commerci
avail
volkova
et
al
mean
bmi
improv
compar
patient
ivacaftor
annual
risk
pex
hospit
preval
cf
relat
diabet
cfrd
distal
intestin
obstruct
syndrom
dio
reduc
septemb
fda
approv
lumacaftorivacaftor
use
children
age
year
two
copi
mutat
result
open
label
phase
trial
support
approv
present
milla
et
al
patient
n
receiv
lumacaftorivacaftor
week
safeti
find
similar
observ
older
patient
respiratori
relat
event
common
particip
experienc
elev
liver
transaminas
uln
discontinu
due
advers
event
requir
one
patient
due
elev
liver
transaminas
one
due
rash
resolv
discontinu
sweat
chlorid
level
decreas
mean
mmoll
ci
p
bmi
increas
mean
p
qualiti
life
score
lung
function
index
improv
week
wherea
statist
signific
chang
predict
mean
ci
p
lumacaftorivacaftor
current
studi
children
age
year
two
copi
mutat
clinic
trial
ivacaftor
patient
cf
carri
specif
gate
mutat
age
year
result
klimb
extens
studi
kiwi
clinic
trial
evalu
long
term
safeti
efficaci
ivacaftor
children
age
year
cftr
gate
mutat
present
rosenfeld
et
al
children
n
receiv
weight
base
dose
ivacaftor
safeti
data
clinic
outcom
similar
kiwi
two
patient
discontinu
treatment
due
elev
liver
transaminas
sweat
chlorid
valu
decreas
significantli
mean
sd
mmoll
p
signific
improv
bmi
pancreat
function
measur
fecal
elastas
immunoreact
trypsinogen
similar
seen
kiwi
result
phase
iia
studi
novel
potenti
patient
gate
mutat
present
de
boeck
et
al
patient
n
data
provid
treat
week
two
dose
level
administ
sequenti
two
week
seriou
advers
event
report
decreas
sweat
chlorid
seen
phase
open
label
studi
mutat
n
also
demonstr
signific
decreas
sweat
chlorid
predict
improv
washout
level
seriou
advers
event
includ
cpk
increas
dio
one
patient
pex
one
patient
novel
corrector
also
evalu
phase
sequenti
dose
studi
van
de
steen
et
al
appear
safe
well
toler
phase
ii
studi
ongo
second
corrector
enter
phase
goal
tripl
combin
cftr
modul
singh
et
al
addit
cftr
modul
current
phase
trial
deuter
ivacaftor
cftr
potenti
compar
ivacaftor
singl
dose
studi
dose
escal
studi
uttamsingh
et
al
appear
safe
well
toler
pk
data
support
daili
dose
phase
clinic
trial
cf
patient
gate
mutat
underway
preliminari
phase
result
studi
cftr
amplifi
mutat
agnost
therapi
select
increas
amount
cftr
protein
cell
present
safeti
concern
identifi
among
cf
healthi
control
n
although
final
studi
result
avail
moud
et
al
final
novel
oligonucleotid
repair
mrna
theoret
result
normal
cftr
protein
studi
phase
open
label
studi
nasal
topic
effect
npd
measur
peopl
one
two
copi
mutat
henig
et
al
proof
concept
studi
demonstr
restor
cftr
function
chang
chlorid
respons
week
treatment
nasal
applic
safe
phase
trial
inhal
formul
current
recruit
particip
levofloxacin
inhal
solut
li
approv
patient
cf
chronic
pa
infect
european
medicin
agenc
ema
canada
yet
approv
fda
use
us
ema
approv
li
base
result
demonstr
compar
inhal
tobramycin
ti
week
day
treatment
onoff
cycl
patient
cf
age
year
older
chronic
pa
infect
mpex
studi
convers
doubl
blind
studi
li
meet
primari
outcom
time
next
pex
signific
differ
result
subgroup
analysi
patient
age
older
enrol
studi
present
fisher
et
al
outcom
measur
defin
chang
lung
function
baselin
end
treatment
cycl
risk
pex
mean
chang
baselin
end
treatment
significantli
higher
li
compar
ti
second
third
treatment
cycl
time
pex
increas
li
group
p
compar
ti
march
us
fda
grant
li
qualifi
infecti
diseas
product
qidp
design
regulatori
discuss
ongo
inhal
vancomycin
aerovanc
develop
cf
patient
persist
staphylococcu
aureu
mrsa
infect
pharmacokinet
pk
result
phase
ii
studi
aerovanc
present
marich
et
al
cf
patient
p
enrol
random
studi
subgroup
patient
treatment
evalu
sputum
blood
pk
sputum
concentr
accumul
throughout
month
maintain
mic
mcgml
two
dose
level
mg
bid
minim
system
exposur
plasma
accumul
marich
c
et
al
data
present
ongo
italian
earli
mrsa
erad
trial
compar
treatment
trimethoprimsulfamethoxazol
rifampin
versu
observ
subject
new
onset
mrsa
infect
data
patient
enrol
date
show
trend
toward
lower
mrsa
posit
cultur
rate
month
therapi
reach
signific
neri
et
al
inhal
mannitol
approv
adult
year
older
cf
ema
yet
approv
us
canada
studi
phase
ii
random
studi
children
cf
de
boeck
et
al
children
age
year
n
mean
sd
random
receiv
week
inhal
mannitol
placebo
follow
week
treatment
signific
improv
therapi
rel
differ
group
ci
p
pulmonari
exacerb
lower
inhal
mannitol
group
advers
event
less
common
compar
receiv
placebo
highlight
microbiolog
present
treatment
guidelin
novel
antimicrobi
approach
toronto
cf
center
present
pa
erad
protocol
blanchard
et
al
sinc
patient
new
onset
pa
receiv
singl
cours
ti
follow
repeat
cycl
fail
clear
patient
ongo
pa
posit
cultur
treat
week
iv
therapi
result
children
show
erad
one
two
cycl
ti
respect
requir
iv
therapi
clear
cumul
success
rate
chronic
treatment
refractori
pa
often
describ
biofilm
growth
mode
although
recent
concept
reexamin
parsek
featur
consist
pa
biofilm
growth
cf
includ
local
difficult
erad
infect
biofilm
appear
convers
cf
deriv
pa
isol
often
poor
biofilm
form
capac
bacteria
grow
high
densiti
stationari
phase
show
decreas
kill
antibiot
dr
parsek
also
present
cellular
metabol
function
consist
biofilm
versu
biofilm
hypothesi
either
case
novel
treatment
approach
stationari
biofilm
growth
necessari
one
exampl
novel
therapi
target
biofilm
inhal
algin
oligosaccharid
oligog
guluron
oligom
deriv
seawe
algin
thought
disrupt
bacteri
biofilm
reduc
sputum
viscos
phase
ii
random
studi
cf
adult
evalu
safeti
toler
efficaci
oligog
administ
day
patient
cf
pa
infect
final
result
pend
pressler
et
al
vitro
exposur
matur
biofilm
colistin
without
oligog
show
enhanc
kill
combin
pritchard
et
al
addit
oligog
interfer
signal
pathway
pa
jack
et
al
disrupt
pa
biofilm
directli
langloi
et
al
therapi
thought
enhanc
autophagi
mean
enhanc
host
degrad
pa
show
promis
result
vitro
cultur
murin
infect
model
bonfield
et
al
anoth
novel
antimicrobi
candid
undergo
test
nebul
treatment
mix
paburkholderia
infect
mice
infect
intranas
bacteria
decreas
mortal
treat
compar
treatment
inhal
tobramycin
inhal
aztreonam
tetz
et
al
cf
center
chicago
present
experi
inhal
meropenem
subject
age
year
brackett
et
al
main
side
effect
cough
inhal
sever
enough
stop
therapi
one
patient
allerg
reaction
one
patient
subject
complet
week
cours
show
improv
respons
better
infect
pa
compar
three
subject
infect
b
cepacia
vaccin
mean
prevent
infect
pa
aureu
present
symposium
goldberg
among
challeng
bacteri
epitop
often
shield
host
immun
detect
may
chang
earli
later
stage
infect
perform
clinic
trial
infect
patient
appropri
measur
endpoint
sever
pa
vaccin
studi
neg
inconclus
includ
octaval
flagella
direct
vaccin
vaccin
direct
oprf
fail
bival
vaccin
shown
promis
result
pursu
compani
aureu
vaccin
trial
ventil
associ
pneumonia
evalu
two
compani
oct
clinic
manag
mycobacteri
ntm
infect
address
relev
recent
publish
consensu
manag
guidelin
haworth
rational
unusu
dose
interv
recommend
ntm
treatment
guidelin
order
decreas
side
effect
drug
interact
discuss
olivi
emphasi
place
consensu
document
start
point
serv
mean
observ
studi
rather
definit
treatis
epidemiolog
ntm
highlight
exampl
lower
preval
avium
complex
younger
patient
europ
compar
us
seemingli
lower
virul
infect
europ
nick
identif
subspeci
mycobacteria
relev
prognosi
exampl
abscessu
subspeci
massiliens
contain
partial
delet
gene
reduc
risk
develop
macrolid
resist
compar
abscessu
ss
abscessu
often
carri
gene
hand
massilliens
implic
transmiss
cf
cystic
fibrosi
foundat
therapeut
cfft
fund
biobank
ntm
isol
ongo
denver
colorado
test
share
clonal
lineag
within
us
hasan
et
al
inform
transplant
set
ntm
present
specif
dearth
evid
around
transplant
elig
individu
cf
infect
ntm
specif
abscessu
noon
mortal
due
mycobacteri
infect
vari
differ
public
yet
surgic
site
skin
infect
due
abscessu
frequent
current
consensu
guidelin
recommend
evalu
indic
therapi
ntm
prior
referr
transplant
complex
multidrug
therapi
set
immunosuppress
risk
complic
need
consid
sever
microbiom
studi
address
longitudin
aspect
airway
infect
ahm
et
al
acosta
et
al
abil
microb
grow
mucin
hunter
metabol
activ
anaerob
bacteria
growth
anaerob
commun
pa
test
use
vitro
growth
model
simul
zone
within
mucu
plug
progress
aerob
anaerob
condit
quinn
et
al
mathemat
model
test
observ
dynam
respons
chang
ph
size
airway
model
antibiot
administr
lower
ph
wider
radiu
airway
led
increas
anaerob
antibiot
kill
anaerob
bacteria
allow
pa
thrive
research
suggest
model
support
observ
cf
pex
associ
bloom
ferment
anaerob
lower
mucu
ph
dr
quinn
also
present
case
vignett
support
clinic
relev
ferment
hypothesi
sputum
sampl
patient
fail
antibiot
therapi
test
use
combin
rrna
sequenc
transcriptom
metabolom
integr
bioinformat
assess
metabolit
product
match
transcriptom
profil
microbiom
detect
data
avail
within
h
quinn
et
al
viral
infect
contribut
diseas
onset
progress
either
directli
interact
bacteria
present
sever
poster
demonstr
mechan
pa
infect
follow
viral
infect
epitheli
cell
vitro
melvin
et
al
hendrick
et
al
frequenc
virus
examin
prospect
first
month
life
cf
infant
use
nasopharyng
swab
pcr
detect
deschamp
et
al
overal
detect
rate
coronaviru
preval
although
odd
ratio
viru
posit
enhanc
number
symptom
record
infant
symptomat
associ
lung
function
lower
airway
inflamm
viru
posit
use
palivizumab
cf
infant
born
evalu
use
us
cffpr
fink
et
al
infant
receiv
prophylaxi
decreas
trend
time
children
receiv
prophylaxi
lower
weight
respiratori
symptom
time
start
palivizumab
higher
pa
incid
first
year
life
without
prophylaxi
lung
function
avail
children
age
year
show
differ
two
cohort
effort
enhanc
process
transit
pediatr
adult
cf
care
receiv
support
recent
year
onecf
learn
leadership
collabor
partnership
dartmouth
institut
microsystem
academi
cf
foundat
cff
sever
center
report
process
outcom
onecf
llc
project
includ
overal
program
develop
barnico
et
al
develop
handoff
tool
metcalf
et
al
assess
satisfact
johnson
et
al
success
crowley
et
al
optim
time
transit
assess
emphas
individu
base
prepared
prefer
use
experi
patient
prior
transfer
meet
adult
physician
pediatr
clinic
social
worker
facilit
transit
sadeghi
et
al
nasr
age
appear
best
predictor
transit
readi
despit
variabl
acquisit
diseas
skill
lapp
specif
counsel
topic
help
improv
readi
skill
sawicki
et
al
import
track
progress
toward
transit
goal
use
target
ongo
educ
individu
patient
emphas
facilit
transit
coordin
cooney
transit
cf
care
team
lung
transplant
team
may
occur
individu
advanc
lung
diseas
tallarico
describ
current
practic
goal
develop
formal
transit
program
transplant
candid
tallarico
et
al
special
care
peopl
cf
undergo
transplant
also
highlight
context
outcom
improv
outcom
center
perform
cf
lung
transplant
overal
transplant
volum
appear
less
import
hay
et
al
diseas
characterist
may
predict
outcom
investig
link
transplant
registri
data
cffpr
dasenbrook
et
al
us
transplant
data
canadian
data
quon
et
al
use
predict
wait
list
surviv
also
describ
bernstein
et
al
concern
exist
outcom
highest
risk
one
center
report
differ
surviv
rel
stabl
patient
high
risk
patient
need
substanti
respiratori
support
bridg
therapi
gray
et
al
studi
may
help
transform
approach
referr
list
manag
care
peopl
advanc
cf
lung
diseas
requir
thought
commun
goal
wish
choic
around
lung
transplant
end
life
care
primari
palli
care
case
mean
palli
care
provid
cf
care
team
rather
palli
care
specialist
receiv
greater
attent
valu
palli
care
increasingli
recogn
mani
patient
caregiv
lack
familiar
palli
care
prieur
et
al
unmet
need
area
symptom
manag
commun
prognosi
opportun
engag
patient
advanc
care
plan
acp
identifi
hobler
et
al
patient
cf
age
older
caregiv
recept
palli
care
educ
educ
appear
increas
knowledg
also
reduc
fear
uncertainti
relat
topic
hailey
et
al
studi
advanc
care
plan
acp
among
us
cf
center
actual
suggest
attent
issu
recent
year
past
know
practic
vari
center
basil
report
low
frequenc
convers
intens
care
option
like
intub
note
variabl
peopl
desir
hear
prognost
estim
basil
et
al
addit
patient
cope
style
may
affect
comfort
level
particip
acp
may
help
inform
approach
acp
graham
et
al
suggest
counsel
around
complex
treatment
option
individu
given
high
preval
distress
symptom
cf
effect
symptom
manag
anoth
import
aspect
care
regardless
diseas
sever
pain
manag
opioid
current
receiv
nation
attent
use
opioid
cf
fraught
concern
controversi
due
concern
abus
addict
side
effect
one
center
report
success
implement
inpati
pain
manag
algorithm
emphas
multimod
approach
lehman
et
al
addit
pain
routin
screen
commonli
reveal
physic
psycholog
distress
necessit
intervent
cf
care
team
member
walker
et
al
interact
may
occur
physic
emot
symptom
exampl
depress
associ
dyspnea
pain
anxieti
regardless
lung
diseas
sever
dain
et
al
associ
prompt
provid
consid
impact
physic
emot
symptom
well
individu
function
statu
engag
daili
care
mental
health
receiv
great
deal
attent
nacfc
mani
interest
abstract
present
follow
intern
guidelin
establish
cff
european
cf
symposium
session
member
cff
mental
health
guidelin
advisori
committe
present
overview
task
educ
train
consult
guidanc
research
work
group
continu
move
import
work
forward
smith
role
mental
health
coordin
review
attent
mental
health
provid
differ
background
train
could
effect
serv
role
kooney
sher
dvorak
mental
health
screen
caught
attent
patient
caregiv
particularli
care
center
receiv
financi
support
cff
mental
health
coordin
homa
et
al
sever
center
report
experi
guidelin
implement
includ
screen
receiv
patient
caregiv
prieur
et
al
beenen
et
al
practic
ethic
issu
caregiv
screen
blair
et
al
roach
et
al
butcher
et
al
plan
program
assess
qualiti
improv
nicolai
et
al
barrier
implement
prieur
et
al
creativ
solut
lack
mental
health
resourc
geograph
divers
popul
prieur
et
al
wolf
et
al
posit
impact
mental
health
intervent
result
screen
akmal
et
al
smith
et
al
frederick
report
advers
health
outcom
patient
screen
posit
depress
depress
teen
lower
peer
worrisom
declin
year
period
teen
adult
depress
predict
versu
predict
without
depress
p
frederick
et
al
lower
health
relat
qualiti
life
score
also
note
across
sever
domain
greater
symptom
depress
anxieti
et
al
find
highlight
critic
import
address
mental
health
concern
routin
part
cf
care
cff
launch
qualiti
improv
qi
initi
acceler
improv
deliveri
cf
care
sinc
major
cf
center
us
particip
formal
program
learn
qi
techniqu
appli
center
center
worldwid
share
vision
exemplari
care
cf
patient
section
highlight
import
clinic
qi
work
showcas
nacfc
focu
measur
improv
concept
determin
real
world
valu
deliveri
high
qualiti
care
cffpr
remain
power
tool
assess
patient
outcom
qi
schechter
colleagu
report
use
cf
registri
smart
report
gener
individu
patient
run
chart
nutrit
measur
bmi
schechter
et
al
report
use
clinic
team
tool
assess
consist
earli
recognit
poor
outcom
center
report
dramat
respons
overal
improv
lung
function
predict
predict
emerg
sourc
data
qi
cf
patient
famili
experi
care
survey
homa
et
al
nearli
cf
program
activ
involv
measur
patient
famili
feedback
individu
cf
care
center
increas
dissemin
survey
present
opportun
center
measur
patient
experi
benchmark
among
center
avail
report
tool
identifi
opportun
improv
process
care
measur
patient
experi
may
use
outcom
measur
center
improv
clinic
flow
commun
access
care
hoffert
et
al
compar
two
model
clinic
flow
tradit
individu
provid
interview
team
interview
adopt
team
interview
approach
reduc
patient
wait
time
overal
clinic
length
increas
patient
staff
satisfact
hoffert
et
al
redesign
clinic
flow
process
map
pdsa
cycl
reduc
lobbi
wait
time
increas
quarterli
clinic
attend
increas
access
yearli
lab
assess
power
et
al
phan
et
al
use
telemedicin
clinic
visit
western
australia
receiv
patient
rural
remot
area
high
satisfact
increas
clinic
attend
wood
et
al
annual
respiratori
therapi
assess
video
telemedicin
encount
increas
patient
understand
airway
clearanc
therapi
satisfact
similar
encount
use
telemedicin
review
airway
clearanc
therapi
lester
et
al
patient
experi
use
tool
assess
impact
redesign
clinic
system
ad
insight
parent
patient
partner
integr
facet
develop
care
deliveri
system
concept
activ
collabor
clinician
patient
produc
servic
parent
famili
partner
cf
famili
advisori
board
increasingli
involv
develop
qi
intervent
prepar
transit
pediatr
adult
care
improv
hospit
experi
johnson
st
ong
et
al
electron
dashboard
individu
trend
bmi
patient
goal
treatment
effect
pilot
test
across
five
cf
center
prickett
et
al
savant
et
al
novel
tool
patient
provid
increas
patient
feel
empower
direct
plan
agenda
incorpor
upstream
identif
patient
concern
creation
care
deliveri
process
anticip
posit
patient
experi
increas
commun
share
goal
commit
care
center
use
data
sourc
cffpr
patient
famili
experi
survey
among
resourc
cf
commun
assess
valu
care
symposium
entitl
deliv
care
evolv
health
care
landscap
explor
role
cf
commun
assess
balanc
qualiti
valu
care
dwight
simon
panel
expert
repres
physician
cff
privat
public
payer
initi
rich
discuss
challeng
defin
valu
high
qualiti
care
grow
cost
cf
care
prioriti
public
privat
sector
payer
among
theme
discuss
advocaci
cff
power
data
tool
cffpr
highlight
opportun
cf
commun
use
test
system
care
shape
health
care
landscap
cf
commun
advantag
tackl
upcom
challeng
determin
valu
emerg
qi
work
across
center
center
activ
assess
patient
level
factor
influenc
daili
care
real
world
help
determin
valu
uptak
lumacaftorivacaftor
use
variabl
slower
ivacaftor
sawicki
et
al
system
care
assess
side
effect
patient
use
may
benefici
assess
valu
anstead
et
al
ong
et
al
integr
pharmaci
team
improv
patient
adher
measur
monthli
medic
possess
ratio
intermountain
pediatr
cf
center
streamlin
counsel
assess
cost
access
schwab
et
al
encourag
test
share
goal
set
skill
assess
program
pociask
et
al
brown
et
al
clinic
attend
improv
financi
incent
allevi
cost
ga
increas
quarterli
visit
attend
dubos
et
al
engag
patient
convers
sustain
daili
care
emerg
standard
therapi
critic
assess
balanc
valu
qualiti
care
frederick
et
al
cf
commun
continu
benefit
innov
biomed
research
patient
key
import
studi
benefit
clinic
research
augment
qi
work
test
intervent
decreas
gap
effect
clinic
practic
real
world
use
clinic
team
obtain
qi
train
cff
sponsorship
dartmouth
learn
leadership
collabor
improv
train
inaugur
cff
qi
fair
prior
nacfc
electr
showcas
multitud
qi
intervent
throughout
cf
commun
includ
introduct
cf
pilot
learn
network
pln
pln
qi
network
initi
cf
program
common
aim
improv
cf
care
deliveri
outcom
build
infrastructur
collabor
learn
qi
fair
also
featur
virtual
improv
program
fundament
promis
provid
remot
way
center
particip
qi
learn
stay
inform
best
techniqu
perform
qi
center
cffpr
tool
provid
mean
measur
improv
effort
rigor
qi
cf
evolv
toward
implement
scienc
studi
mechan
health
care
intervent
adopt
dissemin
interfac
collabor
qi
biomed
research
cf
commun
remain
forefront
mission
deliv
best
care
peopl
live
cf
nacfc
present
updat
mani
advanc
cf
research
care
progress
continu
made
understand
basic
pathophysiolog
cftr
mucu
infect
cf
lung
implic
new
treatment
strategi
multipl
pharmaceut
treatment
aim
improv
cftr
activ
clinic
trial
pipelin
clinic
manag
cf
evolv
rapidli
new
approach
airway
infect
improv
manag
adult
cf
sever
lung
diseas
qi
initi
expand
order
move
new
therapi
effect
standard
clinic
practic
goal
everi
person
cf
receiv
option
exemplari
care
infanc
adulthood
